ANTIVIRAL THERAPY

Scope & Guideline

Advancing the frontier of antiviral research.

Introduction

Immerse yourself in the scholarly insights of ANTIVIRAL THERAPY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1359-6535
PublisherSAGE PUBLICATIONS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationANTIVIR THER / Antivir. Ther.
Frequency8 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The journal 'ANTIVIRAL THERAPY' primarily focuses on the development, evaluation, and optimization of antiviral therapies for viral infections, particularly those affecting human health. It encompasses a broad spectrum of research areas, methodologies, and clinical applications.
  1. Antiviral Drug Development:
    Research on new antiviral agents, including their mechanisms of action, efficacy, and safety profiles.
  2. Clinical Trials and Observational Studies:
    Investigation of antiviral therapies through controlled trials, real-world studies, and retrospective analyses to assess treatment outcomes.
  3. Resistance Mechanisms:
    Studies focused on understanding viral resistance to antiviral medications, including genotypic and phenotypic analyses.
  4. Co-infection Studies:
    Exploration of the interactions and treatment implications of co-infections, particularly between HIV, hepatitis viruses, and other pathogens.
  5. Public Health and Epidemiology:
    Research addressing the epidemiology of viral infections and the impact of antiviral therapies on public health outcomes.
  6. Innovative Therapeutic Approaches:
    Development and assessment of novel treatment strategies, including combination therapies, long-acting formulations, and personalized medicine.
The journal has experienced evolving trends that reflect the current scientific landscape and public health needs. Emerging themes indicate a shift towards innovative research areas and pressing global health challenges.
  1. COVID-19 and Post-Acute Sequelae:
    An increasing number of studies are addressing the impact of COVID-19, including treatment approaches and the long-term effects of the virus on various populations.
  2. Monoclonal Antibody Therapies:
    Research focusing on the use of monoclonal antibodies in treating viral infections, particularly COVID-19 and other emerging viruses, is gaining traction.
  3. HIV Treatment Innovations:
    There is a growing focus on novel treatment regimens, including long-acting injectables and dual therapy approaches, reflecting ongoing advancements in HIV care.
  4. Mechanistic Studies of Viral Pathogenesis:
    Studies elucidating the mechanisms by which viruses evade immune responses and develop resistance are increasingly prominent, particularly in relation to emerging viruses.
  5. Integrated Care Models for Co-infections:
    Research on integrated care approaches for managing co-infections, particularly among vulnerable populations, is becoming more common as co-morbidities are recognized as critical factors in treatment.

Declining or Waning

While the journal has consistently published cutting-edge research, some themes have shown a declining trend over recent years. These waning scopes suggest a shift in focus or reduced interest in certain areas of antiviral therapy.
  1. Traditional Antiviral Agents:
    Research on older antiviral agents, such as acyclovir or older nucleoside analogs, has decreased as newer therapies and mechanisms gain prominence.
  2. Vaccine Development:
    While still relevant, the volume of publications specifically focused on vaccine development against viral infections has waned compared to other therapeutic strategies.
  3. HIV/AIDS Related Stigma Studies:
    Research examining the social stigma related to HIV/AIDS treatment and care has become less frequent, possibly due to a broader focus on clinical outcomes and therapy effectiveness.
  4. Longitudinal Studies in Stable Populations:
    Long-term studies examining stable populations with established treatment regimens have decreased, as the focus shifts to dynamic clinical settings and emerging therapies.

Similar Journals

Viral Hepatit Dergisi-Viral Hepatitis Journal

Exploring breakthroughs in viral hepatitis care.
Publisher: GALENOS PUBL HOUSEISSN: 1307-9441Frequency: 3 issues/year

Viral Hepatit Dergisi - Viral Hepatitis Journal, published by GALENOS PUBL HOUSE, is a preeminent journal dedicated to advancing the field of viral hepatitis research. With an ISSN of 1307-9441 and an E-ISSN of 2147-2939, it serves as a vital platform for the dissemination of cutting-edge studies and clinical findings related to the prevention, diagnosis, and treatment of viral hepatitis. The journal aims to foster collaboration among researchers, medical professionals, and students by providing open access to high-quality research articles and reviews. Although specific impact metrics such as H-Index are not detailed, the journal is well-regarded in its field, contributing significantly to the understanding of viral hepatitis and its global implications. Positioned in Istanbul, Turkey, it draws upon a rich academic tradition, ensuring comprehensive coverage of the subject. This journal is indispensable for anyone invested in the fight against viral hepatitis, enriching the scholarly literature while promoting informed practices in healthcare.

JOURNAL OF CLINICAL VIROLOGY

Pioneering Innovative Solutions in Virology
Publisher: ELSEVIERISSN: 1386-6532Frequency: 12 issues/year

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Journal of Virus Eradication

Catalyzing breakthroughs in epidemiology and immunology.
Publisher: MEDISCRIPT LTDISSN: 2055-6640Frequency: 4 issues/year

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

ANTI-CANCER DRUGS

Transforming Insights into Effective Cancer Solutions
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Annual Review of Virology

Exploring the forefront of viral research.
Publisher: ANNUAL REVIEWSISSN: 2327-056XFrequency: 1 issue/year

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.

VIROLOGICA SINICA

Bridging Knowledge Gaps in Virology and Human Health
Publisher: KEAI PUBLISHING LTDISSN: 1674-0769Frequency: 6 issues/year

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.

JOURNAL DE MYCOLOGIE MEDICALE

Advancing Understanding of Fungal Infections
Publisher: MASSON EDITEURISSN: 1156-5233Frequency: 4 issues/year

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

CHEMOTHERAPY

Illuminating Pathways in Infectious Disease Treatment
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Infectious Diseases and Therapy

Elevating research to combat infectious diseases worldwide.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Advances in Virology

Exploring the Frontiers of Infectious Diseases
Publisher: HINDAWI LTDISSN: 1687-8639Frequency: 1 issue/year

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.